| CAS |
69884-00-0 |
| Chinese Name |
拟人参皂苷F11 |
| English Name |
Pseudoginsenoside F11 |
| Synonyms |
Ginsenoside A1 |
| Molecular Formula |
C42H72O14 |
| Molecular Weight |
801.01 |
| Solubility |
Soluble in DMSO |
| Purity |
HPLC≥98% |
| Appearance |
White to off-white Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL |
MFCD00803938 |
| SMILES |
C[C@@]([C@@]12C)(C[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]3O)([H])[C@@H]3O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O)[C@@]5([H])C6(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@]7(O[C@@H](C(C)(O)C)CC7)C)([H])CC2)([H])[C@]5(CC[C@@H]6O)C |
| InChIKey |
JBGYSAVRIDZNKA-NKECSCAMSA-N |
| InChI |
InChI=1S/C42H72O14/c1-19-28(46)30(48)32(50)35(52-19)55-33-31(49)29(47)23(18-43)54-36(33)53-22-17-41(8)24(39(6)13-11-25(45)37(2,3)34(22)39)16-21(44)27-20(10-14-40(27,41)7)42(9)15-12-26(56-42)38(4,5)51/h19-36,43-51H,10-18H2,1-9H3/t19-,20-,21+,22-,23+,24+,25-,26+,27-,28-,29+,30+,31-,32+,33+,34-,35-,36+,39+,40+,41+,42-/m0/s1 |
| PubChem CID |
21633072 |
| Target Point |
PPARγ |
| Passage |
Cell Cycle;DNA Damage/DNA Repair;Metabolic Enzyme&Protease |
| Background |
It can be used to resist the loss of learning and memory ability induced by scopolamine, morphine and methamphetamine in mice. |
| Biological Activity |
Pseudoginsenoside F11, a natural product found in American ginseng but not in Asian ginseng, is a novel partial PPARγ agonist.[1] |
| In Vitro |
Pseudoginsenoside F11(PF11)promotes the differentiation of 3T3-L1 preadipocytes. It promotes adipogenesis by activating PPARγ[1]. PF11 significantly suppresses the release of ROS and proinflammatory mediators induced by LPS in a microglial cell line N9 including NO，PGE2，IL-1β，IL-6 and TNF-α. Moreover，PF11 inhibits interaction and expression of TLR4 and MyD88 in LPS-activated N9 cells，resulting in an inhibition of the TAK1/IKK/NF-κB signaling pathway. PF11 also inhibited the phosphorylation of Akt and MAPKs induced by LPS in N9 cells[2]. |
| In Vivo |
In in vivo studies，PF11 mitigated the microglial activation and proinflammatory factors expression obviously in both cortex and hippocampus in mice injected intrahippocampally with LPS. PF11 exerts anti-neuroinflammatory effects on LPS-activated microglial cells by inhibiting TLR4-mediated TAK1/IKK/NF-κB，MAPKs and Akt signaling pathways. It may exert therapeutic effects for neurodegenerative disease associated with neuroinflammation[2]. |
| Cell Experiment |
3T3-L1 preadipocytes are induced to differentiate with 0，20，40 μM Pseudoginsenoside F11(p-F11)or 0.5 μM rosiglitazone in the absence or presence of 20 μM GW9662 for 8 days.[1] |
| Data Literature Source |
[1] Wu G，et al. PPAR Res. 2013，2013: 701017.
[2] Wang X，et al. Neuropharmacology. 2014，79:642-56. |
| Unit |
Bottle |
| Specification |
5mg 10mg 10mM*1mL in DMSO |
English
中文
Manual Download
